Business Description
Anavex Life Sciences Corp
NAICS : 325412
SIC : 8731
ISIN : US0327973006
Description
Anavex Life Sciences Corp is a clinical-stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system diseases with high unmet need. It analyzes genomic data from clinical studies to identify biomarkers, which are used to select patients that will receive the therapeutic benefit for the treatment of neurodegenerative and neurodevelopmental diseases. Its necessary compound ANAVEX 2-73 is being developed to treat Alzheimer's disease, Parkinson's disease, and potentially other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder. The company's operating segment is into developing novel therapies for the management of CNS diseases.
Financial Strength
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | No Debt | |||||
| Equity-to-Asset | 0.92 | |||||
| Interest Coverage | No Debt | |||||
| Piotroski F-Score | 3/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | -3.1 | |||||
| 3-Year EPS without NRI Growth Rate | -9.9 | |||||
| 3-Year FCF Growth Rate | 1.7 | |||||
| 3-Year Book Growth Rate | 57.9 |
Momentum Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 66.83 | |||||
| 9-Day RSI | 67 | |||||
| 14-Day RSI | 67.03 | |||||
| 6-1 Month Momentum % | 44.91 | |||||
| 12-1 Month Momentum % | -13.37 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 12.04 | |||||
| Quick Ratio | 12.04 | |||||
| Cash Ratio | 11.81 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -9.8 | |||||
| Shareholder Yield % | -0.16 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -30.14 | |||||
| ROA % | -27.82 | |||||
| ROIC % | -2455.67 | |||||
| ROCE % | -32.1 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 5.9 | |||||
| Price-to-Tangible-Book | 5.93 | |||||
| EV-to-EBIT | -14.08 | |||||
| EV-to-Forward-EBIT | -10.52 | |||||
| EV-to-EBITDA | -14.08 | |||||
| EV-to-Forward-Revenue | 18.93 | |||||
| EV-to-FCF | -20.9 | |||||
| Price-to-Net-Current-Asset-Value | 5.93 | |||||
| Price-to-Net-Cash | 6.02 | |||||
| Earnings Yield (Greenblatt) % | -7.1 | |||||
| FCF Yield % | -3.95 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Anavex Life Sciences Corp Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | |||
| EPS (TTM) (€) | -0.473 | ||
| Beta | 1.34 | ||
| Volatility % | 94.53 | ||
| 14-Day RSI | 67.03 | ||
| 14-Day ATR (€) | 0.407568 | ||
| 20-Day SMA (€) | 7.6855 | ||
| 12-1 Month Momentum % | -13.37 | ||
| 52-Week Range (€) | 2.989 - 9.714 | ||
| Shares Outstanding (Mil) | 84.8 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Anavex Life Sciences Corp Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Anavex Life Sciences Corp Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Anavex Life Sciences Corp Frequently Asked Questions
What is Anavex Life Sciences Corp(STU:12X1)'s stock price today?
The current price of STU:12X1 is €8.48. The 52 week high of STU:12X1 is €9.71 and 52 week low is €2.99.
When is next earnings date of Anavex Life Sciences Corp(STU:12X1)?
The next earnings date of Anavex Life Sciences Corp(STU:12X1) is 2025-02-07 Est..
Does Anavex Life Sciences Corp(STU:12X1) pay dividends? If so, how much?
Anavex Life Sciences Corp(STU:12X1) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers